You are here: Industry Insights > Market News > Sanofi adopts TriNetX platform to speed clinical trials

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

water filter

WATER FILTER FOR WATER PURIFIER

DUST BAG

Small dust filter

HUMIDIFIER FILTER

Oil fume adsorption filter

Sanofi adopts TriNetX platform to speed clinical trials

biospectrumasiaJanuary 24, 2018

Tag: Sanofi , TriNetX

Favorites

TriNetX has announced that it will be assisting Sanofi by using patient EHRs to optimize recruitment, streamline trial investigators’ workflows and otherwise impact the design of investigational drug trials. Sanofi has made similar arrangements to bolster its clinical trials with Science 37 and Evidation in March and July of last year, respectively.

The goal of the partnership is to simplify and to make better, earlier and more informed decisions. Sanofi has fully implemented the TriNetX technology across its entire portfolio last January.

Cambridge, MA based TriNetX operates a cloud-accessible federated health research platform.

Previous:Agilent Technologies Inc. selected as 2017 Company of the Year

Next:German researchers propose new medication for malaria

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Sanofi adopts TriNetX platform to speed clinical trials | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

Sanofi adopts TriNetX platform to speed clinical trials

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may like
More>>

Sanofi adopts TriNetX platform to speed clinical trials

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may likeMore>>

You may like
More>>